Eligibility clarifications

1. Patients being treated for existing mould infections (suspected or otherwise) are excluded.
2. Patients with a relapse of AML who will receive a remission-induction course are eligible to be entered into the study. (Re-induction for refractory or relapsed cases is mentioned in Appendix B ‘Chemotherapy of AML and MDS’).
3. Patients with ALL undergoing chemotherapy (not for SCT) are not eligible for inclusion.
4. Patients given high-dose chemotherapy and autologous stem cell transplant are not eligible for inclusion.
5. Patients undergoing a reduced intensity conditioning regimen are not eligible for inclusion.
6. FLAMSA patients are eligible, because the chemotherapeutic preface usually results in a prolonged and deep neutropenia similar to that seen in remission-induction of AML/MDS.